Nursing care
Enoxaparin: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 4 min read · Updated September 2026
Short answer
Enoxaparin (Lovenox) is a low molecular weight heparin given by subcutaneous injection into the abdomen for VTE prophylaxis and treatment. Do not expel the air bubble in a prefilled syringe, do not aspirate, and do not rub the site afterward. Unlike unfractionated heparin, routine aPTT monitoring is not required.
What it does and why it is prescribed
Enoxaparin is a low molecular weight heparin that inhibits factor Xa, with a smaller effect on thrombin than unfractionated heparin. It is prescribed for prophylaxis and treatment of deep vein thrombosis and pulmonary embolism, and for patients with acute coronary syndrome or those undergoing certain orthopaedic and abdominal surgeries.
Its more predictable pharmacokinetics compared with unfractionated heparin come from its more consistent binding to plasma proteins and cells. This predictability is what allows it to be dosed by body weight without routine coagulation monitoring, and is the main reason it has largely replaced unfractionated heparin for prophylactic and many treatment indications.
Nursing considerations before giving it
Confirm the dose is weight-based and check renal function, since enoxaparin is renally cleared and accumulates in significant renal impairment, raising bleeding risk. Review for other anticoagulants, antiplatelet agents, or NSAIDs, and check platelet count if the patient has had prior heparin exposure, given the risk of heparin-induced thrombocytopenia.
Select an injection site in the abdomen, at least five centimetres from the umbilicus, and rotate sites between doses. Do not administer intramuscularly. If the patient is having a spinal or epidural procedure, confirm timing with the prescriber, since enoxaparin carries a boxed warning for spinal or epidural haematoma when combined with neuraxial anaesthesia.
What to monitor
Monitor for bleeding: bruising at injection sites, gum bleeding, blood in urine or stool, and, more seriously, signs of internal bleeding such as back pain or abdominal distension. Check platelet counts periodically, particularly in the first two weeks, to catch heparin-induced thrombocytopenia early.
Routine coagulation monitoring is not required for most patients, which is a key difference from unfractionated heparin. There is no aPTT to check and no dose titration based on it. Anti-factor Xa levels are used only in specific situations, such as significant obesity, renal impairment, pregnancy, or paediatric dosing, not as a routine check for a standard adult on prophylactic or treatment dosing.
Side effects versus adverse effects
Expected effects include local bruising, minor pain, or a small haematoma at the injection site, which are common and not usually a reason to stop therapy. Mild elevation in liver enzymes has also been reported and is usually not clinically significant.
Adverse effects requiring escalation include major bleeding from any site, a platelet count drop of 50 percent or more from baseline suggesting heparin-induced thrombocytopenia, and any sign of spinal or epidural haematoma such as new back pain with leg weakness or bowel or bladder dysfunction in a patient who has had neuraxial anaesthesia.
What to hold for and when to call
Hold the dose and call the prescriber for active bleeding, a platelet count that has dropped sharply from baseline, or a planned spinal or epidural procedure within the window the prescriber specifies. Confirm renal function results before giving a dose in a patient with known or worsening renal impairment.
Call promptly for any new neurological symptoms in a patient who has had spinal anaesthesia or a lumbar puncture while on enoxaparin, since this can signal an epidural haematoma and requires urgent imaging. Also call for signs of major bleeding regardless of the injection schedule.
Patient teaching
Teach patients or caregivers who will self-inject at home to use the abdomen, avoiding a two-inch radius around the navel, and to rotate sites left and right. If the syringe is prefilled with an air bubble, tell them not to expel it before injecting, since it is part of the correct dose and helps clear the needle track.
Instruct them to pinch a fold of skin, insert the needle at a 90-degree angle, inject slowly, and remove the needle without rubbing the site afterward, since rubbing increases bruising. Tell them to watch for and report unusual bruising, bleeding gums, dark or tarry stools, or blood in the urine.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pharmacology practice questions are the closest set to what this page covers.
One question from the pharmacology set
A client with heart failure is started on furosemide 40 mg PO daily. Which findings should the nurse report to the provider before administering the next dose? Select all that apply.
Rationale
Furosemide is a loop diuretic, so the two things you are watching are potassium and kidney function. A potassium of 2.9 mEq/L is below the 3.5–5.0 reference range and puts the client at risk for dysrhythmia — hold and report. Muscle cramps with palpitations are the clinical face of that same hypokalemia, so they are reported together, not separately. A creatinine that doubles signals the diuresis has outrun renal perfusion. A blood pressure of 132/78 and a 1 kg loss are the expected response to the drug working, not reasons to hold it.
Answer: A, D, E
Common questions
Should the air bubble be removed from an enoxaparin syringe before injecting?
No. The air bubble in a prefilled enoxaparin syringe should not be expelled. It is built into the manufactured dose and helps push the full amount of medication into the tissue and clear the needle track, reducing the chance of medication tracking back along the needle path.
Does enoxaparin require aPTT monitoring like heparin?
No. Enoxaparin's predictable pharmacokinetics mean routine aPTT monitoring is not required for most patients, unlike unfractionated heparin. Anti-factor Xa levels are reserved for specific situations such as significant renal impairment, obesity, or pregnancy, not routine dosing checks.
Why shouldn't you rub the injection site after giving enoxaparin?
Rubbing the site after subcutaneous injection increases local tissue trauma and can worsen bruising or haematoma formation. Apply gentle pressure only if needed to stop minor bleeding, without rubbing or massaging the area.
Can enoxaparin be given intramuscularly?
No. Enoxaparin must be given subcutaneously, not intramuscularly, because intramuscular injection significantly increases the risk of haematoma formation given the drug's anticoagulant effect. It is administered into the abdominal subcutaneous tissue as standard practice.
More on pharmacology
Guides on this